MX338489B - Derivados de hidantoina utiles como inhibidores de kv3. - Google Patents

Derivados de hidantoina utiles como inhibidores de kv3.

Info

Publication number
MX338489B
MX338489B MX2013006343A MX2013006343A MX338489B MX 338489 B MX338489 B MX 338489B MX 2013006343 A MX2013006343 A MX 2013006343A MX 2013006343 A MX2013006343 A MX 2013006343A MX 338489 B MX338489 B MX 338489B
Authority
MX
Mexico
Prior art keywords
inhibitors
derivatives useful
hydantoin derivatives
hydantoin
compounds
Prior art date
Application number
MX2013006343A
Other languages
English (en)
Spanish (es)
Other versions
MX2013006343A (es
Inventor
Giuseppe Alvaro
Charles Large
Agostino Marasco
Anne Decor
Paolo Dambruoso
Simona Tommasi
Original Assignee
Autifony Therapeuticts Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/068946 external-priority patent/WO2011069951A1/en
Priority claimed from GBGB1020607.6A external-priority patent/GB201020607D0/en
Priority claimed from GBGB1109508.0A external-priority patent/GB201109508D0/en
Priority claimed from GBGB1113757.7A external-priority patent/GB201113757D0/en
Application filed by Autifony Therapeuticts Ltd filed Critical Autifony Therapeuticts Ltd
Publication of MX2013006343A publication Critical patent/MX2013006343A/es
Publication of MX338489B publication Critical patent/MX338489B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2013006343A 2010-12-06 2011-12-06 Derivados de hidantoina utiles como inhibidores de kv3. MX338489B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2010/068946 WO2011069951A1 (en) 2009-12-11 2010-12-06 Imidazolidinedione derivatives
GBGB1020607.6A GB201020607D0 (en) 2010-12-06 2010-12-06 Novel compounds
GBGB1109508.0A GB201109508D0 (en) 2011-06-07 2011-06-07 Novel compounds
GBGB1113757.7A GB201113757D0 (en) 2011-08-10 2011-08-10 Novel compounds
PCT/GB2011/052414 WO2012076877A1 (en) 2010-12-06 2011-12-06 Hydantoin derivatives useful as kv3 inhibitors

Publications (2)

Publication Number Publication Date
MX2013006343A MX2013006343A (es) 2013-09-13
MX338489B true MX338489B (es) 2016-04-18

Family

ID=45464001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006343A MX338489B (es) 2010-12-06 2011-12-06 Derivados de hidantoina utiles como inhibidores de kv3.

Country Status (17)

Country Link
US (13) US9346790B2 (enExample)
EP (1) EP2649066B1 (enExample)
JP (2) JP5913357B2 (enExample)
KR (1) KR101862375B1 (enExample)
CN (1) CN103328467B (enExample)
AU (1) AU2011340258C1 (enExample)
BR (1) BR112013013914B1 (enExample)
CA (1) CA2817205C (enExample)
DK (1) DK2649066T3 (enExample)
EA (2) EA023768B1 (enExample)
ES (1) ES2560304T3 (enExample)
IL (3) IL226256A0 (enExample)
MX (1) MX338489B (enExample)
PL (1) PL2649066T3 (enExample)
SG (2) SG190203A1 (enExample)
WO (1) WO2012076877A1 (enExample)
ZA (1) ZA201403529B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012015868A2 (pt) * 2009-12-11 2017-06-20 Autifony Therapeutics Ltd derivados de imidazolidinadiona
SG190203A1 (en) 2010-12-06 2013-06-28 Autifony Therapeutics Ltd Hydantoin derivatives useful as kv3 inhibitors
EP2718285B1 (en) 2011-06-07 2016-03-16 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
ES2576628T3 (es) * 2011-12-06 2016-07-08 Autifony Therapeutics Limited Derivados de hidantoína útiles como inhibidores de Kv3
WO2013175211A1 (en) * 2012-05-22 2013-11-28 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
WO2013182851A1 (en) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
US9416115B2 (en) * 2013-12-20 2016-08-16 Gilead Scineces, Inc. Fused heterocyclic compounds as ion channel modulators
KR102381584B1 (ko) 2014-01-16 2022-04-04 에프엠씨 코포레이션 제초제로서의 피리미디닐옥시 벤젠 유도체
WO2015140326A1 (en) * 2014-03-21 2015-09-24 Biotage Ab Method and apparatus for the equilibration of a packed chromatography column
CN103980205B (zh) * 2014-06-05 2016-01-20 武汉格罗宁根医药科技有限公司 N-3-取代磺酰胺乙基-5-环丙烷螺环乙内酰脲衍生物及其制备方法和应用
TWI713530B (zh) 2015-06-05 2020-12-21 美商艾佛艾姆希公司 作為除草劑之嘧啶氧基苯衍生物
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) * 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
WO2018109484A1 (en) 2016-12-16 2018-06-21 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
CA3062135A1 (en) * 2017-05-02 2018-11-08 Fmc Corporation Pyrimidinyloxy benzo-fused compounds as herbicides
WO2018220762A1 (ja) * 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
CN107556262B (zh) * 2017-08-14 2020-05-22 四川大学 一种2-取代基芳并噁唑的制备方法
US11486289B2 (en) * 2018-07-03 2022-11-01 Cummins Emission Solutions Inc. Body mixing decomposition reactor
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
ES2988842T3 (es) 2018-10-16 2024-11-21 Autifony Therapeutics Ltd Nuevos compuestos
TWI877067B (zh) 2018-11-30 2025-03-11 日商大塚製藥股份有限公司 雜環化合物
GB201821066D0 (en) * 2018-12-21 2019-02-06 Univ Oxford Innovation Ltd Sleep modulation
AU2019296526A1 (en) * 2019-03-25 2021-09-16 Bionomics Limited Substituted-N-heteroaryl compounds and uses thereof
EP4100402A1 (en) 2020-02-06 2022-12-14 Autifony Therapeutics Limited Kv3 modulators
US11638606B2 (en) 2020-04-15 2023-05-02 Bard Peripheral Vascular, Inc. Bipolar electrosurgical pleura sealing device, system, and method of operating same
EP3901152A1 (en) 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
CN112213428A (zh) * 2020-10-13 2021-01-12 辽宁科技大学 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法
JP2024530208A (ja) 2021-08-10 2024-08-16 アウトイフオンイ トヘラペウトイクス リミテッド カリウムチャネルモジュレーター
KR20230084419A (ko) * 2021-12-03 2023-06-13 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474170A (en) * 1964-01-23 1969-10-21 Fmc Corp Pesticidal carbamates of dihydrobenzofuranols
US4143055A (en) * 1978-03-27 1979-03-06 Gruppo Lepetit S.P.A. 2,4,6-trisubstituted-2,3-dihydro-benzofuran derivatives
DE3015090A1 (de) 1980-04-19 1981-10-22 Basf Ag, 6700 Ludwigshafen ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen
DE3133405A1 (de) 1981-08-24 1983-03-10 Basf Ag, 6700 Ludwigshafen 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide
US4675403A (en) 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
JP2514945B2 (ja) * 1987-02-05 1996-07-10 三井石油化学工業株式会社 芳香族アミン誘導体
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3836175A1 (de) 1988-10-24 1990-05-03 Bayer Ag Fluor enthaltende phenole
CA2007830A1 (en) * 1989-01-18 1990-07-18 Shuji Ozawa 2,3-dihydro-3, 3-dimethyl-5-trifluoromethanesulfonyloxy-benzofurans, process for producing them and herbicides containing them
MX22406A (es) 1989-09-15 1994-01-31 Pfizer Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat).
JPH03153606A (ja) * 1989-11-10 1991-07-01 Mitsui Petrochem Ind Ltd 除草剤組成物
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
DK123493D0 (da) 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
WO1996036229A1 (en) 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
BR9608520A (pt) 1995-05-17 1999-06-08 Du Pont Composto composição fungida e método para controlede doenças de plantas
KR19990028230A (ko) 1995-06-20 1999-04-15 미리암 디. 메코너헤이 살절지동물성 및 살진균성 시클릭 아미드
EP0934283A2 (en) 1996-08-01 1999-08-11 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
WO1998023155A1 (en) 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
EP0944314A1 (en) 1996-11-26 1999-09-29 E.I. Du Pont De Nemours And Company Methyl substituted fungicides and arthropodicides
AU6040398A (en) 1997-01-30 1998-08-25 E.I. Du Pont De Nemours And Company Fungicidal compositions
JP4171549B2 (ja) 1998-01-28 2008-10-22 大正製薬株式会社 含フッ素アミノ酸誘導体
JP2000072731A (ja) 1998-08-31 2000-03-07 Taisho Pharmaceut Co Ltd 4−置換−2−アミノビシクロ[3.1.0]ヘキサン−2,6−ジカルボン酸誘導体及び製薬用組成物
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 6−フルオロビシクロ[3.1.0]ヘキサン誘導体
US7008954B1 (en) 1999-07-23 2006-03-07 Shionogi & Co., Ltd. Th2 differentiation inhibitors
EP1273287A1 (en) 2000-04-04 2003-01-08 Shionogi & Co., Ltd. Oily compositions containing highly fat-soluble drugs
WO2001076582A1 (fr) 2000-04-05 2001-10-18 Shionogi & Co., Ltd. Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
WO2003048134A1 (en) 2001-12-05 2003-06-12 Japan Tobacco Inc. Triazole compound and medicinal use thereof
JP2005521676A (ja) 2002-02-07 2005-07-21 ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ オピオイドレセプター作動性4−(3−ヒドロキシフェニル)または4−(3−アルコキシフェニル)−1,2,4−トリアゾール化合物
FI20030030A0 (fi) * 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
ES2290743T3 (es) 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0325175D0 (en) 2003-10-28 2003-12-03 Novartis Ag Organic compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US20060211697A1 (en) 2004-12-08 2006-09-21 Liren Huang 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
AU2007245022A1 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CA2608436C (en) 2005-05-13 2015-03-24 The Regents Of The University Of California Diarylhydantoin compounds and their use in the treatment of hyperproliferative disorders
EP3100727B1 (en) 2006-03-27 2018-08-22 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
EP2146717A4 (en) 2007-04-20 2010-08-11 Deciphera Pharmaceuticals Llc KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYOLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES
EP2252592A1 (de) 2008-02-07 2010-11-24 Sanofi-Aventis Arylchalcogeno-arylalkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
CN103396402A (zh) * 2008-09-02 2013-11-20 赛诺菲-安万特 取代的氨基茚满及其类似物以及其医药用途
EP2379534A1 (en) * 2008-12-22 2011-10-26 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
BR112012015868A2 (pt) 2009-12-11 2017-06-20 Autifony Therapeutics Ltd derivados de imidazolidinadiona
TW201144298A (en) * 2009-12-14 2011-12-16 Hoffmann La Roche Heterocyclic antiviral compounds
SG190203A1 (en) * 2010-12-06 2013-06-28 Autifony Therapeutics Ltd Hydantoin derivatives useful as kv3 inhibitors
EP2718285B1 (en) 2011-06-07 2016-03-16 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
JP2018533579A (ja) 2015-10-30 2018-11-15 ザ・ジョンズ・ホプキンス・ユニバーシティー 高分子量かつ密な被覆を有する粘液浸透粒子

Also Published As

Publication number Publication date
US20140323508A1 (en) 2014-10-30
US11583527B2 (en) 2023-02-21
EA201490922A1 (ru) 2015-03-31
SG11201402529RA (en) 2014-06-27
US20160251340A1 (en) 2016-09-01
US20190000849A1 (en) 2019-01-03
EA023768B1 (ru) 2016-07-29
WO2012076877A1 (en) 2012-06-14
IL253102A0 (en) 2017-08-31
US20200360379A1 (en) 2020-11-19
SG190203A1 (en) 2013-06-28
US10835534B2 (en) 2020-11-17
AU2011340258B2 (en) 2016-05-19
DK2649066T3 (en) 2016-01-11
ZA201403529B (en) 2020-03-25
JP5913357B2 (ja) 2016-04-27
EA201390609A1 (ru) 2014-01-30
HK1190395A1 (en) 2014-07-04
US20190192516A1 (en) 2019-06-27
CN103328467A (zh) 2013-09-25
US9833452B2 (en) 2017-12-05
US20180036308A1 (en) 2018-02-08
EA027532B1 (ru) 2017-08-31
CN103328467B (zh) 2016-08-10
US20150336936A1 (en) 2015-11-26
US20220054490A1 (en) 2022-02-24
IL253104A0 (en) 2017-08-31
BR112013013914A2 (pt) 2016-09-13
US10555945B2 (en) 2020-02-11
JP6118927B2 (ja) 2017-04-19
US20170273981A1 (en) 2017-09-28
KR101862375B1 (ko) 2018-05-29
US10265316B2 (en) 2019-04-23
EP2649066A1 (en) 2013-10-16
US20200179385A1 (en) 2020-06-11
JP2013544873A (ja) 2013-12-19
JP2016145215A (ja) 2016-08-12
AU2011340258A1 (en) 2013-05-30
EP2649066B1 (en) 2015-10-21
MX2013006343A (es) 2013-09-13
US20130267510A1 (en) 2013-10-10
IL253102B (en) 2018-04-30
AU2011340258C1 (en) 2016-10-20
CA2817205C (en) 2020-04-07
US11197859B2 (en) 2021-12-14
PL2649066T3 (pl) 2017-04-28
US11541052B2 (en) 2023-01-03
KR20130138815A (ko) 2013-12-19
IL226256A0 (en) 2013-07-31
US20210023084A1 (en) 2021-01-28
ES2560304T3 (es) 2016-02-18
US9346790B2 (en) 2016-05-24
US9422272B2 (en) 2016-08-23
US20160317537A1 (en) 2016-11-03
CA2817205A1 (en) 2012-06-14
US9133175B2 (en) 2015-09-15
BR112013013914B1 (pt) 2021-10-26
US10098881B2 (en) 2018-10-16

Similar Documents

Publication Publication Date Title
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
IN2015DN01156A (enExample)
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
JO2892B1 (en) CYP inhibitors 17
CA2871471C (en) Dna-pk inhibitors
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
MY181898A (en) Heterocyclic compounds and uses thereof
EA201170832A1 (ru) Пуриновые соединения
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
TN2011000673A1 (en) Bace inhibitors
UA105911C2 (uk) Сульфонамідні похідні
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
MX2012004780A (es) Inhibidores de akt.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EP2603216A4 (en) HETEROARYLE AND USES THEREOF
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX342947B (es) Tratamiento de diabetes tipo 2.
CA2887539C (en) Azaquinazoline carboxamide derivatives
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
EA201270728A1 (ru) Пуриновые соединения
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)

Legal Events

Date Code Title Description
FG Grant or registration